StemRIM
Research StemRIM (4599.T) on Bullrun: market cap JPY 10.28B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4599.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 10.28B
- Financial periodFY2025
Valuation Snapshot
latest market cap is JPY 10.28B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | n/a | n/a | -31.16 | n/a | n/a | n/a |
| FY2024 | JPY 0 | -JPY 2.02B | -JPY 1.89B | n/a | -32.98 | JPY 8.41B | JPY 0 | JPY 8.89B |
| FY2023 | JPY 2.35B | JPY 168.35M | JPY 1.13B | n/a | 2.69 | JPY 10.22B | JPY 531.00K | JPY 10.37B |
| FY2022 | JPY 22.98M | -JPY 1.95B | -JPY 1.40B | n/a | -32.92 | JPY 8.88B | JPY 3.67M | JPY 9.40B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 10.28B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About StemRIM
StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, liver cirrhosis, and knee osteoarthritis. It also provides pre-clinical stage products, including TRIM3 and TRIM4 for the treatment of various tissue damage diseases;
ETFs that hold StemRIM
US-listed ETFs
StemRIM is held by one US-listed ETF, going by the latest portfolio it filed with the SEC:
| ETF | Weight | Fee |
|---|---|---|
| iShares International Small-Cap Equity Factor ETF (ISCF) | 0.01% | 0.24% |
Portfolios as filed with the SEC on Form N-PORT, dated July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is StemRIM's market cap?
StemRIM's market capitalization is JPY 10.28B.
What does StemRIM do?
StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, liver cirrhosis, and knee osteoarthritis. It also provides pre-clinical stage products, including TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a stem cell gene therapy.